Compare MEI & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MEI | TECX |
|---|---|---|
| Founded | 1946 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 581.1M | 618.9M |
| IPO Year | 1994 | 2018 |
| Metric | MEI | TECX |
|---|---|---|
| Price | $14.53 | $29.12 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $9.00 | ★ $75.20 |
| AVG Volume (30 Days) | ★ 727.1K | 220.2K |
| Earning Date | 03-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.61% | N/A |
| EPS Growth | ★ 42.94 | 40.70 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $908,300,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 11.24 | N/A |
| 52 Week Low | $4.88 | $14.39 |
| 52 Week High | $20.38 | $39.53 |
| Indicator | MEI | TECX |
|---|---|---|
| Relative Strength Index (RSI) | 39.49 | 38.75 |
| Support Level | $13.22 | $27.53 |
| Resistance Level | $18.11 | $31.39 |
| Average True Range (ATR) | 1.22 | 2.41 |
| MACD | -0.40 | -0.74 |
| Stochastic Oscillator | 1.47 | 2.01 |
Methode Electronics Inc supplier of custom-engineered solutions with sales, engineering, and manufacturing locations in North America, Europe, the Middle East, and Asia. It designs, engineers, and produces mechatronic products for Original Equipment Manufacturers (OEMs) utilizing a broad range of technologies for user interface, light-emitting diode (LED) lighting systems, power distribution, and sensor applications. The firm is organized into various business segments: Automotive, Industrial, Interface, and Medical. The Automotive segment, with the majority of revenue from Europe, the Middle East & Africa (EMEA).
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. The company focuses on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.